Twelve Upcoming IPOs This Week Led by Shake Shack (NYSE: SHAK) Stock

upcoming IPOsThere are 12 upcoming IPOs this week, which marks the busiest five-day stretch for IPOs since the week of Sept. 29. The 12 new IPOs should raise a combined $1 billion.

The most anticipated launch this week is Shake Shack Inc. (NYSE: SHAK). That offering comes at a time when fast-casual restaurant IPOs are on a hot streak.

Burger chain The Habit Restaurants Inc. (Nasdaq: HABT) went public in November and doubled its share price on the first day. Shares of El Pollo Loco Holdings Inc. (Nasdaq: LOCO) leaped 60.2% on its opening day in October. Zoe's Kitchen Inc. (NYSE: ZOES) opened at $25.65 in April. That was 71% higher than its $15 offer price.

Here's a look at the Shake Shack IPO and the rest of this week's upcoming IPOs...

The 12 Upcoming IPOs on This Week's IPO Calendar

Shake Shack Inc. (NYSE: SHAK) is a New York-based fast-casual burger chain with 63 locations. According to Renaissance Capital, a manager of IPO-focused ETFs, SHAK is looking to raise $75 million. It will offer 5 million shares at a $14 to $16 price range. Founded in 2004 as a tiny kiosk in Madison Square Park, Shake Shack has a market value of roughly $533 million. SHAK stock will begin trading on Friday, Jan. 30.

InfraREIT Inc. (NYSE: HIFR) is a real estate investment trust (REIT) that owns electric transmission and distribution assets in Texas. It is the largest IPO of the week, as the company should raise $400 million. At that price, it would be valued at $1.2 billion. The company will offer 20 million shares at a price range of $19 to $21.

REIT IPOs had a solid performance last year. Paramount Group Inc. (NYSE: PGRE) raised $2.3 billion, making it the largest IPO ever for a U.S. REIT. Store Capital Corp. (NYSE: STOR) has gained 17.8% since its November launch. Despite uncertainty around how oil prices may affect electricity demand, REITs offer high-yield dividends. The company will hit the market on Friday, Jan. 30.

Money Morning Members: Continue reading for the rest of this week's upcoming IPOs. For those new to Money Morning, sign up to keep reading - it's completely free...

Spark Therapeutics Inc. (Nasdaq: ONCE) develops gene therapy treatments for retinal deterioration and blood disorders. Spark is expected to raise $88 million by offering 5.5 million shares at a $15 to $17 price range. The company is valued at $378 million. Competitor Avalanche Biotechnologies Inc. (Nasdaq: AAVL) gained 65% on its first day. Spark will hit the market on Friday, Jan. 30.

Ascendis Pharma A/S (Nasdaq: ASND) is a company that creates treatments for growth hormone deficiency (GHD). It has also collaborated with Sanofi SA (NYSE ADR: SNY) and Genentech Inc. to develop diabetes and vision treatments. It was founded in 2007 and is headquartered in Hellerup, Denmark. Ascendis plans to raise $85 million by offering 5 million shares at a $16 to $18 price range. The company sits on a market value of $373 million. Versartis Inc. (Nasdaq: VSAR), another GHD-focused firm, opened last year above its price range and gained 49% on its first day. Ascendis will hit the market on Thursday, Jan. 29.

Entellus Medical Inc. (Nasdaq: ENTL) sells a minimally invasive treatment for people suffering from sinus inflammation. The company was founded in 2006 and is headquartered in Plymouth, Minn. Entellus looks to raise $70 million for its IPO. It will offer 4.4 million shares at a price range of $15 to $17. The company will hit the market on Friday, Jan. 30.

Flex Pharma Inc. (Nasdaq: FLKS) is expected to raise $60 million by offering 4.6 million shares at a price range of $12 to $14. It is currently valued at $231 million. Flex Pharma has grown at an extremely fast clip - it filed for an IPO just 10 months after being founded. FLKS will begin trading on Thursday, Jan. 29.

Avinger Inc. (Nasdaq: AVGR) manufactures catheter technology to treat peripheral artery disease. The company's executive team used to work for FoxHollow Technologies, a catheter company that went public in 2004. Avinger is set for a $60 million deal by selling 4.6 million shares at a $12 to $14 price range. It is valued at $169 million and will debut on Friday, Jan. 30.

Infraredx Inc. (Nasdaq: REDX) is a medical equipment company focused on coronary artery disease. Infraredx develops catheter devices used for identifying coronary plaque. The firm looks to raise $56 million by offering 4 million shares at a $13 to $15 price range. It has a valuation of $213 million. It competes with Avinger Inc., which is going public on the same day. REDX stock will hit the market on Friday, Jan. 30.

Presbia Plc. (Nasdaq: LENS) sells surgically implanted lenses for people with age-related vision loss. The company's procedures take about 10 minutes and costs $3,000. Its treatments are available in 10 countries. Founded in 2007 and available in 10 countries, Presbia plans to raise $50 million by selling 4.2 million shares at an $11 to $13 range. It is valued at $160 million. Presbia faces stiff competition from related medical companies. Those include Entellus Medical Inc. (Nasdaq: ENTL), also debuting on the Nasdaq this week. LENS stock will debut on Wednesday, Jan. 28.

Zosano Pharma Corp. (Nasdaq: ZSAN) is a developer of transdermal products and vaccines. Zosano is currently developing a skin patch that delivers an approved osteoporosis treatment. On Monday, the California-based company increased its proposed deal size. Zosano is now expected to raise $47 million. It will offer 4.3 million shares at a price range of $10 to $12. That's an increase from 3 million shares at the same price range. The company is valued at $133 million. It first filed to raise $70 million last July but postponed the offering. Zosano recently partnered with Eli Lilly and Co. (NYSE: LLY) to commercialize the patch treatment. ZSAN will begin trading on Wednesday, Jan. 28.

TRACON Pharmaceuticals Inc. (Nasdaq: TCON) is a firm that develops antibodies to treat cancer, vision loss, and fibrosis. TRACON has ongoing drug trials that are backed by the National Cancer Institute. The San Diego-based company plans to raise $47 million. It will offer 3.6 million shares at a price range of $12 to $14. It is valued at $164 million and will begin trading on Friday, Jan. 30.

EyeGate Pharmaceuticals Inc. (Nasdaq: EYEG) is a company developing a treatment for eye inflammation. EyeGate postponed its IPO in October, and Renaissance Capital, a manager of IPO-focused ETFs, expects a deal this week. It originally filed to raise $25 million but has since cut that figure in half. The company will offer 1.4 million shares at a $6 to $8 price range.

Tech IPOs in 2015: There were more IPOs in 2014 than any year since 2000. The tech sector dominated the IPO market with giants such as Alibaba and GoPro. And 2015 will be even bigger. That's why we're keeping an eye on the most profitable companies going public this year...